ESC-HFA 2026 9 - 12 May 2026

Efficacy and safety of the microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction (HF-REVERT)

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Cardiovascular Disease
Congress oral presentation
PHASE 2 (RCT)